

The Bromopentadienyl Acrylate Approach to Himbacine


Leon S.-M. Wong, Lisa A. Sharp, Natacha M. C. Xavier, Peter Turner,[†] and Michael S. Sherburn*

School of Chemistry, University of Sydney, Sydney NSW 2006, Australia

m.sherburn@chem.usyd.edu.au

Received April 5, 2002

ABSTRACT



The syntheses of 4,4a-didehydrohimbacine and 4,4a-didehydrohimandravine are presented. Key steps include an intramolecular Diels–Alder reaction of a bromopentadienyl acrylate and Suzuki–Miyaura and Stille coupling reactions.

The structures of himbacine (**1**) and himandravine (**2**) (Figure 1) were reported by Pinhey, Ritchie, and Taylor in 1961.¹ These alkaloids were extracted from *Galbulimima baccata*, a species of tree found in Northern Australia and Papua New Guinea. Himbacine was subsequently found to exhibit strong, selective binding to muscarinic receptors of the M₂ subtype.² Speculation that selective presynaptic muscarinic receptor antagonists might find application in the treatment of neurodegenerative disorders such as Alzheimer's disease³ has provoked extensive synthetic efforts toward *Galbulimima* alkaloids by many groups.^{4–8}

Reported synthetic work toward himbacine to date involves the construction of ring B by way of a Diels–Alder reaction

(Figure 1). Of all possible Diels–Alder-based disconnections that can be applied to the himbacine framework, a ring B




Figure 1. Synthetic approaches to himbacine involving a Diels–Alder reaction to construct the B-ring.

[†] To whom correspondence should be addressed regarding the crystal structure.

(1) Pinhey, J. T.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1961**, *14* 106–134.

(2) (a) Anwar-ul, S.; Gilani, H.; Cobbin, L. B. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1986**, *332*, 16–20. (b) Wang, J. X.; Roeske, W. R.; Wang, W.; Yamamura, H. I. *Brain Res.* **1988**, *446*, 155–158.


(3) Kozikowski, A. P.; Fauq, A. H.; Miller, J. H.; McKinney, M. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 797–802.

(4) (a) Hart, D. J.; Wu, W.-L.; Kozikowski, A. P. *J. Am. Chem. Soc.* **1995**, *117*, 9369–9370. (b) Hart, D. J.; Li, J.; Wu, W.-L.; Kozikowski, A. P. *J. Org. Chem.* **1997**, *62*, 5023–5033.

(5) (a) De Baecke, G.; De Clercq, P. J. *Tetrahedron Lett.* **1995**, *36*, 7515–7518. (b) Hofman, S.; De Baecke, G.; Kenda, B.; De Clercq, P. J. *Synthesis* **1998**, 479–489. (c) Hofman, S.; Gao, L.-J.; Van Dingenen, H.; Hosten, N. G. C.; Van Haver, D.; De Clercq, P. J.; Milanesio, M.; Viterbo, D. *Eur. J. Org. Chem.* **2001**, 2851–2860.

disconnection of 4,4a-didehydrohimbacine appeared to us as the most synthetically attractive, since such a disconnection reveals an intramolecular Diels–Alder (IMDA) reaction involving an acrylate ester derivative of either a [3]-dendralene⁹ or a bromodiene. We recently reported the results of a joint synthetic-computational investigation into the feasibility of the latter approach for the preparation of himbacine,¹⁰ and herein we disclose an extension of this work to 4,4a-didehydrohimbacine and 4,4a-didehydrohimandravine.¹¹ The appearance of a paper by De Clercq and co-workers¹² prompts this preliminary report.

Scheme 1. Synthesis of Bromotricycle **9**^a




^a (a) Pd(PPh₃)₄ (0.10 equiv), Ba(OH)₂ (1.8 equiv), THF–MeOH–H₂O, 25 °C, 15 h, 70%; (b) Bu₄NF (1.5 equiv), THF, 25 °C, 3 h, 94%; (c) CH₂=CHCOCl (1.6 equiv), Et₃N (2.1 equiv), CH₂Cl₂, 25 °C, 0.5 h, 81%; (d) PhCl ([**7**]_{initial} = 10 mM), BHT (0.05 equiv), reflux, 112 h, 81%; **8**:**9** = 86:14; (e) DBU (1.1 equiv), CH₂Cl₂, reflux, 16 h, 97%; (f)¹⁰ PhCl ([**10**]_{initial} = 10 mM), BHT (0.05 equiv), reflux, 156 h, 83%; **11**:**12** = 81:19.

Our synthesis begins (Scheme 1) with a Suzuki–Miyaura coupling between (*S*)-lactic acid derived dibromoalkene **4**¹³ and cyclohexene-1-boronic acid **3**,¹⁴ which, in line with earlier observations by Roush,¹⁵ gave the *Z*-bromodiene **5**

in high selectivity. Deprotection of the silyl ether and esterification of the resulting bromodienol with acryloyl chloride gave IMDA precursor **7**. Dilute (10 mM) solutions of **7** in chlorobenzene undergo a highly stereoselective IMDA reaction upon heating to 132 °C for 5 days at ambient pressure to afford two cycloadducts **8** and **9** in an 86:14 ratio. Both cycloadducts possess the C3,C3a-*anti*-stereochemistry required for himbacine. The stereochemical outcome of the IMDA reaction of **7** mirrors that seen with the acyclic precursor **10**.¹⁰ This close similarity in reaction outcome strongly suggests that the same stereocontrolling influences are at play. Thus, π -diastereofacial selectivity in these reactions is dominated by the development of destabilizing ^{1,3}A strain in transition states leading to the unseen C3,C3a-*syn* isomers. Of the two observed C3,C3a-*anti* products, *trans*-fused *exo*-isomer **8** (cf. **11**) is preferred over its *cis*-fused *endo*-congener **9** (cf. **12**) as a result of the presence of a destabilizing eclipsing interaction between the CH₃ group and H3a in the transition state leading to the latter. The major cycloaddition product **8** is readily converted into the required *cis*-fused isomer **9** in essentially quantitative yield on exposure to DBU.¹⁰

The D-ring-appended vinylstannane side chains required for himbacine and himandravine, **16** and **19**, respectively (Scheme 2), were prepared from the known *N*-Boc piperidine

Scheme 2. Synthesis of D-Ring-Appended Vinyl Stannanes^a



^a (a) (Ph₃PCHBr₂)Br (2.0 equiv), *t*-BuOK (1.9 equiv), THF, RT, 10 min, 81%; (b) LiHMDS (1.2 equiv), THF, –78 °C – RT, 7 h, 90%; (c) Bu₃SnH (2.2 equiv), Pd/dba₃ (0.005 equiv), PPh₃ (0.04 equiv), THF, RT, 6 h, 77%; (d) (Ph₃PCHBr₂)Br (2.0 equiv), *t*-BuOK (1.9 equiv), THF, RT, 7 h, then *n*-BuLi (5.0 equiv), –78 °C, 10 min, 78%; (e) Bu₃SnH (1.1 equiv), AIBN (0.05 equiv), PhH, reflux, 11 h, 61%.

aldehydes **13**¹⁶ and **17**^{7c,16a} through related two- and three-step sequences.¹⁷ In the case of the 2,5-*trans* diastereomer **16**, modified Corey–Fuchs reaction¹⁸ of aldehyde **13** gave

(9) Fielder, S.; Rowan, D. D.; Sherburn, M. S. *Angew. Chem., Int. Ed.* **2000**, 39, 4331–4333.

(10) Cayzer, T. N.; Wong, L. S.-M.; Turner, P.; Paddon-Row, M. N.; Sherburn, M. S. *Chem. Eur. J.* **2002**, 8, 739–750.


(11) Portions of this work were presented by L.S.-M.W. at the Royal Australian Chemical Institute Organic Group 21st Annual Symposium, University of Wollongong, Australia, 29 November 2000.

(6) Baldwin, J. E.; Chesworth, R.; Parker, J. S.; Russell, A. T. *Tetrahedron Lett.* **1995**, 36, 9551–9554.

(7) (a) Chackalamannil, S.; Davies, R. J.; Asberom, T.; Doller, D.; Leone, D. J. *Am. Chem. Soc.* **1996**, 118, 9812–9813. (b) Chackalamannil, S.; Davies, R. J.; Wang, Y.; Asberom, T.; Doller, D.; Wong, J.; Leone, D.; McPhail, A. T. *J. Org. Chem.* **1999**, 64, 1932–1940. (c) Chackalamannil, S.; Davies, R.; McPhail, A. T. *Org. Lett.* **2001**, 3, 1427–1429.

(8) Takadoi, M.; Katoh, T.; Ishiwata, A.; Terashima, S. *Tetrahedron Lett.* **1999**, 40, 3399–3402.

Scheme 3. Synthesis of 4,4a-Didehydrohimbacine **22** and 4,4a-Didehydrohimandravine **23**^a



^a (a) Pd(PPh₃)₄ (0.20 equiv), CuCl (5.0 equiv), LiCl (6.0 equiv), DMSO, 60 °C, 32 h, 73% for R = α -H; 65% for R = β -H; (b) CF₃COOH (80 equiv), CH₂Cl₂, RT, 10 min, then CH₂O (17 equiv), NaBH₃CN (6 equiv), CH₃CN, RT, 16 h, 65% for R = α -H; 60% for R = β -H.

the 1,1-dibromoalkene **14**, which was converted to the *E*-vinylstannane **16** via the 1-bromoalkyne **15** according to Pattenden's hydrostannylation–reductive debromination protocol.¹⁹ Interestingly, better yields were obtained in the 2,5-*cis* series by adopting a one-pot Corey–Fuchs reaction–dehydrobromination–debromination sequence¹⁸ (**17** → **18**) followed by radical hydrostannylation (**18** → **19**).

Cuprous chloride accelerated Stille coupling of vinylstannanes **16** and **19** with bromotricycle **9** proceeded in 73% and 65% yields under conditions reported by Corey and co-workers (Scheme 3).²⁰

Deprotection and reductive methylation of the tetracyclic products **20** and **21** gave 4,4a-didehydrohimbacine **22** and 4,4a-didehydrohimandravine **23** in overall yields of 65% and 60%, respectively. The structure of the latter was confirmed by single-crystal X-ray analysis (Figure 2).²¹

In summary, a short and modular approach to didehydro analogues of biologically important *Galbulimima* alkaloids has been developed. Current efforts involve the application of this general strategy to the synthesis of himbacine.

(12) Cauwenberge, G. V.; Gao, L.-J.; Van Haver, D.; Milanese, M.; Viterbo, D.; De Clercq, P. *J. Org. Lett.* **2002**, *4*, 1579–1582.

(13) (a) Marshall, J. A.; Xie, S. *J. Org. Chem.* **1995**, *60*, 7230–7237. (b) Smith, N. D.; Kocienski, P. J.; Street, S. D. A. *Synthesis* **1996**, 652–666.

(14) This known compound (Renaud, J.; Ouellet, S. G. *J. Am. Chem. Soc.* **1998**, *120*, 7995–7996) was prepared on large scale from 1-lithio-1-cyclohexene (Brandsma, L.; Verkruisje, H. D. *Synth. Commun.* **1990**, *20*, 3367–3369) by boronate ester formation and hydrolysis.




Figure 2. ORTEP diagram of 4,4a-didehydrohimandravine **23**.

Acknowledgment. We thank Dr. Ian Luck (University of Sydney) for assistance with NMR experiments and the Australian Research Council and the University of Sydney for funding.

Supporting Information Available: Experimental procedures and product characterization data for key steps (**3** + **4** → **5**; **7** → **8** + **9**; **16** + **9** → **20**; **20** → **22**), ¹H and ¹³C NMR spectra of all new compounds, and X-ray crystallographic details for 4,4a-didehydrohimandravine **23**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0259746

(15) Roush, W. R.; Moriarty, K. J.; Brown, B. B. *Tetrahedron Lett.* **1990**, *31*, 6509–6512.

(16) (a) Beak, P.; Lee, W. K. *J. Org. Chem.* **1993**, *58*, 1109–1117. (b) Chackalamannil, S.; Davies, R. J.; Wang, Y.; Asberom, T.; Doller, D.; Wong, J.; Leone, D.; McPhail, A. T. *J. Org. Chem.* **1999**, *64*, 1932–1940.

(17) Attempts to carry out this conversion directly (Hodgson, D. M.; Boulton, L. T.; Maw, G. N. *Tetrahedron* **1995**, *51*, 3713–3724) have thus far proven unsuccessful.

(18) Michel, P.; Gennet, D.; Rassat, A. *Tetrahedron Lett.* **1999**, *40*, 8575–8578.

(19) Boden, C. D. J.; Pattenden, G.; Ye, T. *J. Chem. Soc., Perkin Trans. I* **1996**, 2417–2419.

(20) Han, X.; Stoltz, B. M.; Corey, E. J. *J. Am. Chem. Soc.* **1999**, *121*, 7600–7605.

(21) See Supporting Information for full details.